BioCentury | Jan 12, 2019
Finance

Warning: cash needed

...potential capital crunch, then those valuations may become more attractive across the board,” he said. Sailing Capital’s...
BioCentury | Jan 5, 2019
Finance

Ready to launch

...important topic because it has implications on a lot of newer technologies being developed,” said Sailing Capital’s...
...“How do we make this work when people are charging $1 million plus?” Bosun Hau, Sailing Capital...
BioCentury | May 18, 2018
Finance

China comes to Europe

...time, learn the landscape, I think there’s less competition in Europe,” said Bosun Hau of Sailing Capital...
...at €345 million ($428 million). “I think the Chinese valuations are just astronomical.” Bosun Hau, Sailing Capital...
...global development and access to the Chinese market long-term. For instance, Hau noted that because Sailing Capital’s...
BioCentury | Feb 9, 2018
Financial News

CBMG raises about $31M for gene therapy in China

Sailing Capital Overseas Investment Ltd. and its affiliates invested $30.5 million in cell therapy company Cellular Biomedicine Group Inc. (NASDAQ:CBMG) through the sale of 1.7 million shares at $17.80 in a private placement. CBMG said...
BioCentury | Oct 5, 2015
Financial News

Elcelyx Therapeutics completes venture financing

...San Diego, Calif. Business: Endocrine/Metabolic Date completed: 2015-10-01 Type: Venture financing Raised: $20 million Investors: Sailing Capital...
BioCentury | Oct 2, 2015
Financial News

Elcelyx raises $20M toward $40M series E

...in the first tranche of a $40 million series E round led by new investor Sailing Capital...
...IIb trial of Metformin DR, a delayed-release formulation of metformin, to treat Type II diabetes. Sailing Capital's...
Items per page:
1 - 6 of 6
BioCentury | Jan 12, 2019
Finance

Warning: cash needed

...potential capital crunch, then those valuations may become more attractive across the board,” he said. Sailing Capital’s...
BioCentury | Jan 5, 2019
Finance

Ready to launch

...important topic because it has implications on a lot of newer technologies being developed,” said Sailing Capital’s...
...“How do we make this work when people are charging $1 million plus?” Bosun Hau, Sailing Capital...
BioCentury | May 18, 2018
Finance

China comes to Europe

...time, learn the landscape, I think there’s less competition in Europe,” said Bosun Hau of Sailing Capital...
...at €345 million ($428 million). “I think the Chinese valuations are just astronomical.” Bosun Hau, Sailing Capital...
...global development and access to the Chinese market long-term. For instance, Hau noted that because Sailing Capital’s...
BioCentury | Feb 9, 2018
Financial News

CBMG raises about $31M for gene therapy in China

Sailing Capital Overseas Investment Ltd. and its affiliates invested $30.5 million in cell therapy company Cellular Biomedicine Group Inc. (NASDAQ:CBMG) through the sale of 1.7 million shares at $17.80 in a private placement. CBMG said...
BioCentury | Oct 5, 2015
Financial News

Elcelyx Therapeutics completes venture financing

...San Diego, Calif. Business: Endocrine/Metabolic Date completed: 2015-10-01 Type: Venture financing Raised: $20 million Investors: Sailing Capital...
BioCentury | Oct 2, 2015
Financial News

Elcelyx raises $20M toward $40M series E

...in the first tranche of a $40 million series E round led by new investor Sailing Capital...
...IIb trial of Metformin DR, a delayed-release formulation of metformin, to treat Type II diabetes. Sailing Capital's...
Items per page:
1 - 6 of 6